Study Confirms Effectiveness of Nirsevimab Against RSV in Infants

Overview of the Research

A recent study published in the Lancet Child and Adolescent Health reveals that the monoclonal antibody nirsevimab effectively prevents severe respiratory syncytial virus (RSV) infections in infants. Epidemiologists from the University of Toronto and York University conducted an extensive review of published evidence to assess the real-world effectiveness of nirsevimab when prescribed in community settings.

Support for Clinical Trial Data

The Toronto-based researchers stated that their observational findings reinforce existing clinical trial data that supports the use of nirsevimab for treating RSV. There were initial uncertainties about the drug’s effectiveness outside the controlled environments of clinical trials. However, the newly synthesized data suggests a strong case for the routine use of nirsevimab in children who are too young to receive RSV vaccinations.

RSV: A Significant Health Threat to Infants

Prevalence and Risk Factors

Respiratory syncytial virus is the leading cause of hospitalization among infants in the United States. According to the Centers for Disease Control and Prevention (CDC), between 58,000 and 80,000 children under five are admitted to hospitals annually due to RSV. Infants, particularly those born prematurely or with underlying health conditions affecting the heart and lungs, are at heightened risk. This includes children with cystic fibrosis, weakened immune systems, and neuromuscular conditions that complicate swallowing.

Current Limitations of Vaccination

While existing vaccines are effective in preventing severe cases of RSV, they do not adequately protect infants who are too young to be vaccinated or those with compromised immune systems.

Findings from the Meta-Analysis

Impact on Hospitalization Rates

The researchers analyzed data from 27 studies conducted across Italy, France, Spain, Luxembourg, and the United States. Their findings indicate that nirsevimab significantly reduces hospitalizations for RSV in infants under 12 months by as much as 83%.

Specific Outcomes for Infants

Further analysis revealed that among infants under one year old, admissions to intensive care units decreased by 81%, while lower respiratory tract infections were reduced by 75%. Notably, the drug showed greater effectiveness in infants older than three months, preventing 83% of expected RSV-related hospitalizations compared to 76% for those younger than three months.

Understanding Monoclonal Antibodies

Mechanism of Action

Monoclonal antibody therapies like nirsevimab are artificially developed antibodies that replicate the body’s immune response. Instead of relying on vaccines to help the immune system recognize and combat RSV, monoclonal antibodies directly bind to viral particles, preventing them from infecting cells. This approach is particularly beneficial for very young infants, who lack natural antibodies against RSV, allowing the monoclonal antibody to fight the virus while the immune system develops its own defenses.

Reference

Sumsuzzman D, Wang Z, Langley JM, Moghadas SM. Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. May 1st, 2025.